“based on our case, and in line with previous reports, we propose that buccal nabiximols might be an effective addition to ‘acute’ or ‘as required’ tic treatment under specialist guidance,” authors of the case report write .
containing a standardized extract of thc, cbd, other minor cannabinoids, flavonoids and terpenes, the national cancer institute reports that the “cannabinoids interact with g protein-coupled cannabinoid 1 (cb1) receptors in the central nervous system, resulting in analgesic, euphoric and anti-convulsive effects.”
advertisement
a video pre-treatment demonstrates some of the tics.
doctors first tried prescribing 300 mg daily of tiaprid , but it did not ease symptoms of the chronic neurodevelopmental disorder. they then opted for three doses in 15-minute intervals of buccal nabiximols, resulting in a dramatic decrease in symptoms.
advertisement
a study published in 2017, this time involving a 22-year-old patient, found that “treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects.”
subscribe to weekend dispensary , a new weekly newsletter from the growthop.